|
A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 Clinical research trials and A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1. A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 clinical trial. Test subjects oftentimes recieve the best healthcare possible for their A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1 condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1  A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1
A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1
For Condition: Opioid-Related Disorders
Status: No longer recruiting
Sponsor(s): National Institute on Drug Abuse (NIDA) , Britannia
Synopsis: A Phase 3 Placebo-Controlled, Double-Blind Multi-site Trial of Lofexidine for Opiate Withdrawal.
Details: An 11 day inpatient placebo-controlled, double-blind study of 96 opiate dependent, treatment seeking individuals randomized to 2 medication groups: lofexidine and placebo to be conducted in inpatient units at 3 treatment sites.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: Male or female as least 18 yrs of age & above with a current dependence on heroin, morphine or hydromorphone according to DSM4 criteria; subject ; voluntarily given consent and signed informed consent; females using appropriate birth control method. Exclusion Criteria: Additional criteria available during screening at the site
Total Enrollment: 66
Location and Contact Information:
Overall Study Official:
AnnMontgomery, Principal Investigator, National Institute on Drug Abuse (NIDA)
Columbia University
New York City, New York, 10023
United States
Philadelphia Veterans Medical Center
Philadelphia, Pennsylvania, 19104
United States
UCLA Medical Center
Los Angeles, California, 90095
United States
Additional Information:
Study ID Numbers: NIDA-CSP-1020-1;
Study Start Date: April 2001
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00032942
Other Opioid-Related Disorders Studies:
1. Combining Behavioral Treatment with Agonist Maintenance - 1
2. Neurobiology of Opioid Dependence: 4 - 4
3. Isoflurane at Subanesthetic Concentrations - 6
4. Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2
5. Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6
Related Studies:
Other Opioid-Related Disorders Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal - 1
|
|
|
|
|
|
|
|
